Stockholm – December 13, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) will hold its Capital Markets Day in New York tomorrow, Dec 14, between 14:30 – 17:00 CET (8:30-11:00 ET).
For those who cannot attend in New York, you can follow this via a webcast. The registration for this webcast is made through notification via the company’s website or by using the link below.
Webcast and archive link. The Webcast is available for 90 days.
Registration for investors and analysts: RSVP to Alan Lada at firstname.lastname@example.org
For further information, please contact:
Rein Piir, Head of Investor Relations at Oncopeptides
Cell phone: +46 70 853 72 92
This information was submitted for publication at 10:00 CET December 13, 2018.
Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo®), a peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with melflufen compared with established alternative drugs for patients with late-stage multiple myeloma. Melflufen will potentially provide physicians with a new treatment option for patients suffering from this serious disease.
Visit www.oncopeptides.com for more information.